Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of topical tacrolimus
0.05% twice a day in the treatment of ocular graft versus host disease (GVHD).